Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220042

Dhanya Mary Louis, Lakshmi Malavika Nair, D K Vijaykumar, Archana George Vallonthaiel, Jyotsna Yesodharan, Renjitha Bhaskaran, M P Narmadha

{"title":"Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.","authors":"Dhanya Mary Louis, Lakshmi Malavika Nair, D K Vijaykumar, Archana George Vallonthaiel, Jyotsna Yesodharan, Renjitha Bhaskaran, M P Narmadha","doi":"10.3233/BD-220042","DOIUrl":null,"url":null,"abstract":"Background: Endocrine treatment for breast cancer acts largely by inhibiting tumor cell proliferation. The biomarker Ki67 is linked to the proliferative index of the tumour.Objective: To identify the factors affecting the fall in Ki67 value in early-stage hormone receptor (HR) positive breast cancer patients receiving short-term preoperative endocrine therapy in an Indian cohort.Methods: Women with hormone receptor positive, invasive, nonmetastatic, and early breast cancer (<T2, <N1) were assigned to short-term preoperative tamoxifen 20 mg daily (pre-menopausal women) or Letrozole 2.5 mg daily (post-menopausal women) for a minimum of 7 days after noting the baseline Ki67 value from the diagnostic core biopsy specimen. The postoperative Ki67 value was estimated from the surgical specimen, and the factors determining the extent of fall were evaluated.Results: The short-term preoperative endocrine therapy resulted in a reduction in the median Ki67 index, which was significantly greater among postmenopausal women who received Letrozole (63.25 (31.94-80.5)) than among premenopausal women who received Tamoxifen (0 (-28.99-62.25)) (p-value 0.001). The fall in Ki67 value was particularly marked for patients with low-grade tumors with high Estrogen and progesterone receptor expression (p-value < 0.05). The duration of treatment (<2 week or 2-4 week or >4 week) did not affect the fall in Ki67.Conclusion: Preoperative therapy with Letrozole resulted in a more significant fall in Ki67, as compared to therapy with Tamoxifen. Determining the fall in Ki67 value in response to preoperative endocrine therapy could provide an insight into the response to endocrine therapy in luminal breast cancer.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"27-36"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endocrine treatment for breast cancer acts largely by inhibiting tumor cell proliferation. The biomarker Ki67 is linked to the proliferative index of the tumour.

Objective: To identify the factors affecting the fall in Ki67 value in early-stage hormone receptor (HR) positive breast cancer patients receiving short-term preoperative endocrine therapy in an Indian cohort.

Methods: Women with hormone receptor positive, invasive, nonmetastatic, and early breast cancer (

Results: The short-term preoperative endocrine therapy resulted in a reduction in the median Ki67 index, which was significantly greater among postmenopausal women who received Letrozole (63.25 (31.94-80.5)) than among premenopausal women who received Tamoxifen (0 (-28.99-62.25)) (p-value 0.001). The fall in Ki67 value was particularly marked for patients with low-grade tumors with high Estrogen and progesterone receptor expression (p-value < 0.05). The duration of treatment (<2 week or 2-4 week or >4 week) did not affect the fall in Ki67.

Conclusion: Preoperative therapy with Letrozole resulted in a more significant fall in Ki67, as compared to therapy with Tamoxifen. Determining the fall in Ki67 value in response to preoperative endocrine therapy could provide an insight into the response to endocrine therapy in luminal breast cancer.

查看原文本刊更多论文

未知水域:早期乳腺癌术前短期内分泌治疗后Ki67指数下降的意义。

背景:乳腺癌的内分泌治疗主要是通过抑制肿瘤细胞增殖来实现的。生物标志物Ki67与肿瘤的增殖指数有关。目的:在印度的一个队列中，研究早期激素受体(HR)阳性乳腺癌患者接受短期术前内分泌治疗时Ki67值下降的影响因素。方法:激素受体阳性、侵袭性、非转移性、早期乳腺癌患者(结果:术前短期内分泌治疗可降低Ki67指数中位数，绝经后接受来曲唑组(63.25(31.94-80.5))显著高于绝经前接受他莫昔芬组(0 (-28.99-62.25))(p值0.001)。Ki67值的下降在雌激素和孕激素受体高表达的低级别肿瘤患者中尤为明显(p值< 0.05)。治疗时间(4周)对Ki67的下降没有影响。结论:与他莫昔芬相比，术前来曲唑治疗导致Ki67更显著下降。确定术前内分泌治疗后Ki67值的下降有助于了解腔内乳腺癌对内分泌治疗的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.